Update JCOG 1008 and ongoing Japanese trials

Makoto Tahara, M.D, Ph.D

Division of Head and Neck Medical Oncology,

National Cancer Center hospital East, Kashiwa,

JAPAN

JCOG
Japan Clinical Oncology Group

Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with SCCHN

JCOG 1008

Principle Investigator: Makoto Tahara, MD, PhD
Medical Oncology Chair: Naomi Kiyota, MD
Radiation Oncology Chair: Takeshi Kodaira, MD

Study schema: JCOG 1008

Post-operative high-risk HNSCC

- Microscopically margin +
- **ECE +**

RANDOMIZE

Arm A: 3-Weekly CDDP/RT
CDDP 100mg/m^2 on day1, 22, 43
RT 2Gy/fr, 33fr, total 66Gy

Arm B: Weekly CDDP/RT
CDDP 40mg/m^2, weekly
RT 2Gy/fr, 33fr, total 66Gy

Primary endpoint

- phase II part, proportion of complete treatment
- phase III part, overall survival (to test non-inferiority)
- Planned sample size: 260 patients
- Planned accrual period: 5 year
- Participation: 22institutions

JCOG Japan Clinical Oncology Group Can not support other countries

- Funded primarily by the National Cancer Center Research and Development Fund(=Japanese government)
- No received research fund from pharmaceutical company
- Limited fund in Head and Neck group:
  ¥11,000,000=€84,000
  - Used for expense of Data center and conferences
  - No reward for a patient enrollment to each institution
  - Supported by volunteers activities

How to collaborate with JCOG?

- Get fund
- Clinical trial Group which has the data center
- Same protocol
- Combined analysis after completion of each trials.